Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK; Department of Medicine, University and Hospital Trust of Verona, Verona, Italy.
Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK.
Ann Oncol. 2021 Feb;32(2):183-196. doi: 10.1016/j.annonc.2020.11.013. Epub 2020 Nov 26.
This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of 'all-comer' treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.
这篇综述总结了近期关于胰腺癌术前治疗策略的证据，并讨论了在非转移性疾病中迫切需要个性化治疗方法的理由。胰腺癌的分子多样性及其对预后和治疗反应的影响，加上“所有患者”治疗方法未能显著改善患者结局，这要求我们朝着基于基因组的方法转变。这在术前潜在可治愈的环境中尤为重要，因为个性化治疗分配有很大潜力降低胰腺癌死亡率。
